Phase 2 Lymphoma Trial, Recruiting NCT06824883 Sponsor: Peking Union Medical College Hospital Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06824883
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with extranodal NK/T-cell lymphoma (a type of cancer affecting immune cells), confirmed by tissue testing at the study centre.
  • People aged between 18 and 75 years.
  • People who have at least one of the following risk factors: aged 60 or older; experiencing "B symptoms" such as fever, night sweats, or unexplained weight loss; having a lower ability to carry out daily activities (confirm with trial site); having elevated levels of a blood enzyme called LDH; or having a measurable level of a virus called EBV in the blood above a certain threshold.
  • People whose general physical ability to carry out daily activities falls within an accepted range on a standard medical scale (confirm with trial site).
  • People whose bone marrow is producing enough blood cells, based on specific blood test results meeting minimum levels for white blood cells, platelets, and haemoglobin.
  • People whose liver, kidneys, and heart are functioning adequately, based on specific blood test and heart function measurements meeting required levels.

Who may not be able to join:

  • People who have aggressive NK-cell leukaemia (a related but different blood cancer).
  • People whose lymphoma has spread to the central nervous system (brain and spinal cord).
  • People who have experienced certain serious heart conditions in the past 6 months, including heart attack, unstable chest pain, heart failure, uncontrolled irregular heartbeat, or specific abnormalities in the heart's electrical system.
  • People who have an active infection that is not under control.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 010-69155760

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
20 May 2024
Est. completion
20 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete response rate (CRR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov